Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 24 for “"PD-L1 blockade"”.
-
Investigating The Potential of Focused Ultrasound Mediated Hyperthermia on Improving the Efficacy of Anti PD-L1 Blockade in Brain Cancer
… tumor hypoxia and improve the effectiveness of PD-L1 blockade in glioblastoma. Our results show that closed loop MRgFUS mediated mild temperature hyperthermia (~41.5 ̊C) led to a significant reduction (P<0.05) of hypoxic region in GL261 tumor compared to control non-heated tumors. Moreover the …
-
Rationally designing strategies to augment checkpoint therapy in cancer
… programmed cell death ligand 1 (PD-L1) blockade with other ICM therapy and utilises an immunogenic mouse cancer model. This chapter has a key focus on T-cell tolerance, utilising T-cell receptor (TCR) reporter mice to explore the dynamics of orphan nuclear receptor subfamily 4 …
-
PD-1/PD-L1 immunotherapy blockade in solid tumors: role of PD-1/PD-L1 in cancer disease progression
… concept behind cancer and focuses on the use of PD-1 in tumors as a way of immune evasion as well as the use of PD-1/PD-L1 blockade as an innovative target for immunotherapy. Cancer arises from mutagenic events resulting in the presence of abnormal cells and uncontrollable cell proliferation. It …
-
Novel Imaging-Based Techniques Reveal A Role For Pd-1/Pd-L1 In Tumor Immune Surveillance In The Lung
… immune inhibitory receptor Programmed Death 1 (PD-1) on T cells to its ligand PD-L1 has been implicated as a major contributor to tumor induced immune suppression. Clinical trials of PD-L1 blockade have proven effective in unleashing therapeutic anti-tumor immune responses in a subset of …
-
Investigating the Intrinsic Role of Programmed Death-Ligand 1 in Human Cancers.
Programmed death-ligand 1 (PD-L1) expression is a survival mechanism employed by tumours to mediate immune evasion and tumour progression. PD-1/PD-L1-targeted therapies have revolutionised the cancer therapy landscape due to their ability to promote durable anti-tumour immune responses in select …
-
Comprehensive Investigation of Immune Cell Responses in Dengue Virus and SARS-CoV-2 Infections: Insight into T, NK and B Cell Dynamics
… Moreover, we found continuous increased PD-1 expression in CD4+ and CD8+ T cells from severe dengue patients as well as increased levels of multiple co-inhibitory receptors (e.g. LAG-3 and TIM-3), suggesting potential T cell exhaustion. PD-1/PD-L1 blockade resulted in enhanced cytotoxic …
-
Optimierte In-vitro-Testung von Fremdstoffen auf hautsensibilisierendes Potenzial durch CRISPR/Cas9-vermittelten Knockout des Arylhydrocarbon-Rezeptors und Antikörperblockade des inhibitorischen Moleküls programmed cell death-ligand 1
… Rezeptoren Arylhydrocarbon-Rezeptor (AhR) und PD-L1 in dendritischen/monozytären Zellen gentechnisch oder mittels Antikörper ausgeschaltet bzw. blockiert werden, um die nachfolgende Aktivierung von T-Zellen im System zu verstärken. Das entwickelte Testsystem basierte auf dem in der …
-
Comparative Transcriptomic Analysis of Olaparib and Atezolizumab Responses in Triple-Negative Breast Cancer Cell Lines
… (a PARP inhibitor) and Atezolizumab (an anti-PD-L1 antibody), administered individually and in combination, in two TNBC cell lines representing different biological backgrounds: MDA-MB-157 (African American) and MDA-MB-231 (Caucasian), using bioinformatics. Because this in vitro model did not …
-
A SINGLE AMINO ACID SUBSITUTION HUMANIZES MOUSE CD28, INCREASING EFFECTOR AND STEM-LIKE T CELL ACTIVATION
… infection, that were further increased by PD-L1 blockade. Analogous to chronic infection, CD28A210P tumor-bearing mice had increased tumor infiltrating stem-like T cells, which delayed, but ultimately could not control tumor growth. Mechanistically, CD28 A210P enhanced JunB, IL-2, and …
-
Parp Inhibitor Upregulates Pd-L1 Expression and Enhances Cancer-Associated Immunosuppression
… for therapeutic antibodies that block CTLA4, PD-1 and PD-L1, immune checkpoints have emerged as new targets in cancer therapy. In addition, there is accumulating evidence highlighting the role of cancer-associated immunity in patient response to cytotoxic anticancer agents. Inhibitors of poly …
-
cJun Overexpression Sensitizes CAR-T Cells to PD-1 Axis Blockade by Preserving an Intratumoral PD-1⁺ Tcf1⁺ Stem-Like Reservoir
… Additionally, this thesis focuses on the role PD-1⁺ Tcf1⁺ stem-like T cells play in mediating responses to immune checkpoint blockade and examines whether CAR-T cells are capable of forming and maintaining this critical stem-like reservoir in the solid tumor microenvironment (TME). This work …
-
Investigating the Tumour Microenvironment of Non-Small Cell Lung Carcinoma for Anti-Pd-1 Biomarker Discovery
… driver mutations and are now treated with PD-1/PD-L1 blockade as standard therapy. Patients with high tumor cell PD-L1 expression (≥50%, PD-L1high) receive anti-PD-1 monotherapy, but the prognosis for advanced NSCLC is poor. Novel biomarkers to identify this treatment-resistant subset of …
-
Polio Virotherapy of Malignant Glioma Engages the Tumor Myeloid Infiltrate and Triggers Global Microglia Activation
… and is associated with an induction of the PD-L1 immune checkpoint on GAMM. In contrast to transient antitumor effects observed after PVSRIPO monotherapy, combining PVSRIPO with PD1/PD-L1 blockade led to durable remission. Our work implicates GAMM as active drivers of inflammation and …
-
Leveraging the Immunostimulatory Properties of Newcastle disease virus for Vaccination and Cancer Immunotherapy
… Here we explored its combination with CD47 blockade in the B16-F10 melanoma model. Although functional, the reduction in tumor expression of CD47 did not improve the phagocytic ability of antigen presenting cells, their expression of co-stimulatory markers, or the proliferation of T cells …
-
The Dysregulation of T Follicular Regulatory Cells in a Mouse Model of Glioblastoma Multiforme Leads to Humoral Immune Dysfunction
… We additionally show that treatment with PD-L1 monoclonal antibody (mAb) is capable of preventing the expansion of Tvfr cells and is capable of rescuing the development of plasmablasts and plasma cells in tumor-bearing mice. Finally, we show that addition of PD-L1 mAb is capable of …
-
Untersuchung der tumorbiologischen Bedeutung von VISTA im perioperativ/neoadjuvant behandelten Magenkarzinom
… bereits relevante Vertreter wie CTLA-4 und PD-1/PD-L1. VISTA übernimmt die Rolle eines Immun-Checkpoint-Inhibitors und induziert vor allem Effekte der Immunkontrolle. Der Nachweis bei Magenkarzinomen und zugehörigen tumorinfiltrierenden Lymphozyten konnte bereits geführt werden, doch ist …
-
Illuminating the role of cancer associated fibroblasts (CAFs) in tumor development and response to therapy
… in the TME and express immune checkpoint ligands PD-L1 and PD-L2, facilitating the creation of an immunosuppressive tumor stroma. Notably, α-SMA+ CAFs exhibit a tolerogenic phenotype and affect immune cell infiltration and the proteomic contexture of the TME. Moreover, these cells can phagocytose, …
-
An integrated inflammatory and metabolic profiling of stromal-epithelial cell interactions in colorectal cancer
… limited. Particularly, no immune-checkpoint blockade targeting PD-L1 has yet to be approved for CRC. As such, more research is warranted to identify strategies to expand the benefits of immunotherapy to a wider CRC patient population.</p> <p>To date, many studies have highlighted that PD-L1 …
-
T cell receptor signaling and phenotypic landscape of exhausted virus-specific CD8 T cells in chronic LCMV infection
… despite antigen being abundantly present. Both α-PD-L1 blockade and adoptive transfer of naïve target cells increased TCR signaling in vivo, demonstrating that engagement of co-inhibitory receptors such as PD-1 profoundly curtails TCR signaling in vivo. Last, we assessed the heterogeneity of …
-
Characterization of programmed death ligand 1 expression and analyses of its immune-regulatory role in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) represents one of the most fatal malignancies. The dismal prognosis is attributed to the late detection of PDAC in already locally advanced or metastatic stages and high recurrence rates in patients that have undergone curative surgical resection. Since, …
Page 1 of 2